81153-64-2

Basic information

• Product Name: 5-METHYL-1-PHENYL-1H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 5-METHYL-1-PHENYL-1H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER;Ethyl 5-methyl-1-phenylpyrazole-3-carboxylate, tech.;1-Phenyl-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester
• CAS NO: 81153-64-2
• Molecular Formula: C₁₃H₁₄N₂O₂
• Molecular Weight: 230.26
• Mol File: 81153-64-2.mol
• Article Data: 25

Chemical Properties

• Melting Point: 128 - 130°C
• Boiling Point: 128-130°C/2.25mm
• Flash Point: 166.1°C
• Appearance: /
• Density: 1.13
• Vapor Pressure: 4.22E-05mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHYL-1-PHENYL-1H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-1-PHENYL-1H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(81153-64-2)
• EPA Substance Registry System: 5-METHYL-1-PHENYL-1H-PYRAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(81153-64-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 81153-64-2(Hazardous Substances Data)

Usage

General Description

5-Methyl-1-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester is a chemical compound with the molecular formula C14H14N2O2. It is an ethyl ester of 5-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid, and is commonly used in organic synthesis and pharmaceutical research. This chemical is often utilized as a precursor in the production of various drugs and active pharmaceutical ingredients. It is a white to off-white crystalline powder with a melting point of around 134-136°C. 5-Methyl-1-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester is typically handled and stored in accordance with standard laboratory procedures for organic compounds.

InChI:InChI=1/C13H14N2O2/c1-3-17-13(16)12-9-10(2)15(14-12)11-7-5-4-6-8-11/h4-9H,3H2,1-2H3

Upstream product

• 100-63-0 phenylhydrazine 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 126580-15-2 ethyl 2-diazo-4-phenyl-3-pentenoate 
• 64-17-5 ethanol 
• 59-88-1 phenylhydrazine hydrochloride 
• 135351-18-7 (E)-1,1,1-trichloro-4-methoxypent-3-en-2-one 
• 98790-58-0 ethyl (Z)-4-hydroxy-2-oxopent-3-enoate 
• 907178-33-0 (E)-2-(N-methoxy-N-methyl-amino)-4-oxo-2-pentenoic acid ethyl ester 
• 623-47-2 propynoic acid ethyl ester 
• 126580-18-5 ethyl 2-diazo-3-hydroxy-4-phenylpentanoate 
• 135351-18-7 1,1,1-trichloro-4-methoxy-3-penten-2-one 
• 103-03-7 1-phenylsemicarbazide 
• 1067-71-6 Diethyl (2-oxopropyl)phosphonate 
• 28663-68-5 ethyl (phenylhydrazono)chloroacetate 

Downstream Products

• 81153-60-8 6-[m-(5-Methyl-1-phenylpyrazole-3-carboxamido)phenyl]-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole 
• 582297-95-8 CH₃O₄S^(1-)*C₁₄H₁₇N₂O₂⁽¹⁺⁾ 
• 32464-78-1 5-methyl-1-phenylpyrazole-3-carbaldehyde 
• 103753-92-0 5-methyl-4-nitro-1-(4-nitro-phenyl)-1H-pyrazole 
• 103038-19-3 4-(5-methyl-4-nitro-pyrazol-1-yl)-aniline 
• 6831-91-0 5-methyl-1-phenylpyrazole 

Relevant articles and documents

Novel phenylpyrazole derivative and application thereof in medicine for reducing blood sugar

The invention belongs to the field of drug synthesis, and particularly relates to a phenyl pyrazole derivative and a preparation method thereof, and an application thereof in a hypoglycemic drug. The invention provides a novel phenylpyrazole derivative and a general formula thereof. In addition, the invention also provides a preparation method of the derivative and an application of the derivative in hypoglycemic drugs.

Phenyl-1H-pyrazole derivative and application thereof in antitumor drugs

The invention belongs to the technical field of medicines, and provides a phenyl-1H-pyrazole derivative shown as a general formula and a preparation method thereof. The invention also discloses that the phenyl-1H-pyrazole derivative can inhibit the mutual combination of a programmed cell death receptor 1/a programmed cell death ligand 1 (PD-1/PD-L1) and can be used for preparing a PD-1/PD-L1 inhibitor.

Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors

The xanthine oxidase (XO) plays an important role in producing uric acid, and therefore XO inhibitors are considered as one of the promising therapies for hyperuricemia and gout. We have previously reported a series of XO inhibitors with pyrazole scaffold to extend the chemical space of current XO inhibitors. Herein, we describe further structural optimization to explore the optimal heterocycle by replacing the thiazole ring of Febuxostat with 5 heterocycle scaffolds unexplored in this field. All of these efforts resulted in the identification of compound 8, a potent XO inhibitor (IC50 = 48.6 nM) with novel 2-phenylthiazole-4-carboxylic acid scaffold. Moreover, lead compound 8 exhibited hypouricemic effect in potassium oxonate-hypoxanthine-induced hyperuricemic mice. These results promote the understanding of ligand-receptor interaction and might help to design more promising XO inhibitors.